This allowed observation of the known heterogeneity of sIgM signaling capacity in CLL cells (3, 28), where our assay demonstrates substantial variation in response to anti-IgM between different samples (Fig. 2B and C). The gene discussed is CD40LG; the disease is B-cell chronic lymphocytic leukemia.